{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:25:07Z","timestamp":1787660707527,"version":"build-2736575974"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Postdoctor Research Fund of West China Hospital, Sichuan University","award":["2025HXBH134"],"award-info":[{"award-number":["2025HXBH134"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82372831,82403963, 82170785"],"award-info":[{"award-number":["82372831,82403963, 82170785"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Natural Science Foundation of Sichuan, China","award":["2025ZNSFSC1892"],"award-info":[{"award-number":["2025ZNSFSC1892"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program","doi-asserted-by":"crossref","award":["2024YFB3311703-1"],"award-info":[{"award-number":["2024YFB3311703-1"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-026-05109-0","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:11:14Z","timestamp":1774282274000},"page":"3515-3536","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of PSMA PET on the management and clinical outcomes of patients with biochemical failure of prostate cancer after definitive treatment: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"58","author":[{"given":"Guoqing","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhufeng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weizhen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weichao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"issue":"3","key":"5109_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"5109_CR2","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1200\/JCO.2002.11.136","volume":"20","author":"JH Burkhardt","year":"2002","unstructured":"Burkhardt JH et al (2002) Comparing the costs of radiation therapy and radical prostatectomy for the initial treatment of early-stage prostate cancer. J Clin Oncol 20(12):2869\u20132875","journal-title":"J Clin Oncol"},{"issue":"4","key":"5109_CR3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1001\/jama.294.4.433","volume":"294","author":"SJ Freedland","year":"2005","unstructured":"Freedland SJ et al (2005) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294(4):433\u2013439","journal-title":"JAMA"},{"key":"5109_CR4","doi-asserted-by":"publisher","first-page":"1533532","DOI":"10.3389\/fimmu.2024.1533532","volume":"15","author":"Z Jiang","year":"2024","unstructured":"Jiang Z et al (2024) Advances in prostate-specific membrane antigen-targeted theranostics: from radionuclides to near-infrared fluorescence technology. Front Immunol 15:1533532","journal-title":"Front Immunol"},{"issue":"4","key":"5109_CR5","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s00268-005-0544-5","volume":"30","author":"Y Kinoshita","year":"2006","unstructured":"Kinoshita Y et al (2006) Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg 30(4):628\u2013636","journal-title":"World J Surg"},{"issue":"6","key":"5109_CR6","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.eururo.2025.03.003","volume":"87","author":"E Mazzone","year":"2025","unstructured":"Mazzone E et al (2025) A comprehensive systematic review and meta-analysis of the role of Prostate-specific Membrane Antigen Positron Emission Tomography for prostate cancer diagnosis and primary staging before definitive treatment. Eur Urol 87(6):654\u2013671","journal-title":"Eur Urol"},{"issue":"2","key":"5109_CR7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol 86(2):164\u2013182","journal-title":"Eur Urol"},{"key":"5109_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"issue":"2","key":"5109_CR9","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.eururo.2017.08.016","volume":"73","author":"T Knoll","year":"2018","unstructured":"Knoll T et al (2018) Key steps in conducting systematic reviews for underpinning clinical practice guidelines: methodology of the European Association of Urology. Eur Urol 73(2):290\u2013300","journal-title":"Eur Urol"},{"issue":"4","key":"5109_CR10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G et al (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64(4):383\u2013394","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"5109_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH et al (2011) GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). J Clin Epidemiol 64(4):407\u2013415","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"5109_CR12","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/bju.13397","volume":"117","author":"PJ van Leeuwen","year":"2016","unstructured":"van Leeuwen PJ et al (2016) (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int 117(5):732\u2013739","journal-title":"BJU Int"},{"issue":"8","key":"5109_CR13","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/pros.23347","volume":"77","author":"G Habl","year":"2017","unstructured":"Habl G et al (2017) (68) Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: individualized medicine or new standard in salvage treatment. Prostate 77(8):920\u2013927","journal-title":"Prostate"},{"issue":"12","key":"5109_CR14","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.2967\/jnumed.117.192476","volume":"58","author":"TA Hope","year":"2017","unstructured":"Hope TA et al (2017) Impact of (68)Ga-PSMA-11 PET on management in patients with biochemically recurrent prostate cancer. J Nucl Med 58(12):1956\u20131961","journal-title":"J Nucl Med"},{"issue":"3","key":"5109_CR15","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2967\/jnumed.117.202945","volume":"59","author":"J Calais","year":"2018","unstructured":"Calais J et al (2018) Impact of (68)Ga-PSMA-11 PET\/CT on the management of prostate cancer patients with biochemical recurrence. J Nucl Med 59(3):434\u2013441","journal-title":"J Nucl Med"},{"issue":"6","key":"5109_CR16","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1097\/JU.0000000000001000.01","volume":"203","author":"SS Taneja","year":"2020","unstructured":"Taneja SS (2020) Re: 3-year freedom from progression following (68)GaPSMA PET CT triaged management in men with biochemical recurrence post radical prostatectomy. Results of a prospective multi-center trial. J Urol 203(6):1063","journal-title":"J Urol"},{"issue":"5","key":"5109_CR17","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.3390\/curroncol28050282","volume":"28","author":"U Metser","year":"2021","unstructured":"Metser U et al (2021) (18)F-DCFPyL (PSMA) PET in the management of men with biochemical failure after primary therapy: initial clinical experience of an academic cancer center. Curr Oncol 28(5):3251\u20133258","journal-title":"Curr Oncol"},{"issue":"2","key":"5109_CR18","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/0284186X.2019.1669816","volume":"59","author":"J Marzec","year":"2020","unstructured":"Marzec J et al (2020) (68)Ga-PSMA-PET\/CT-directed IGRT\/SBRT for oligometastases of recurrent prostate cancer after initial surgery. Acta Oncol 59(2):149\u2013156","journal-title":"Acta Oncol"},{"issue":"5","key":"5109_CR19","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1111\/ajco.13595","volume":"18","author":"A Davies","year":"2022","unstructured":"Davies A et al (2022) (68) Ga-prostate-specific membrane antigen (PSMA) PET\/CT as a clinical decision-making tool in biochemically recurrent prostate cancer. Asia Pac J Clin Oncol 18(5):e204\u2013e210","journal-title":"Asia Pac J Clin Oncol"},{"issue":"8","key":"5109_CR20","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/RLU.0000000000002169","volume":"43","author":"HD Zacho","year":"2018","unstructured":"Zacho HD et al (2018) 68Ga-PSMA PET\/CT in patients with biochemical recurrence of prostate cancer: a prospective, 2-Center Study. Clin Nucl Med 43(8):579\u2013585","journal-title":"Clin Nucl Med"},{"issue":"12","key":"5109_CR21","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1007\/s00259-020-04809-8","volume":"47","author":"D Deandreis","year":"2020","unstructured":"Deandreis D et al (2020) (68)Ga-PSMA-11 PET\/CT in recurrent hormone-sensitive prostate cancer (HSPC): a prospective single-centre study in patients eligible for salvage therapy. Eur J Nucl Med Mol Imaging 47(12):2804\u20132815","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"5109_CR22","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1007\/s00345-021-03735-0","volume":"39","author":"P Bowden","year":"2021","unstructured":"Bowden P et al (2021) (68)Ga-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial. World J Urol 39(11):4117\u20134125","journal-title":"World J Urol"},{"issue":"12","key":"5109_CR23","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.2967\/jnumed.120.257527","volume":"62","author":"A Afaq","year":"2021","unstructured":"Afaq A et al (2021) A phase II, open-label study to assess safety and management change using (68)Ga-THP PSMA PET\/CT in patients with high risk primary prostate cancer or biochemical recurrence after radical treatment: The PRONOUNCED study. J Nucl Med 62(12):1727\u20131734","journal-title":"J Nucl Med"},{"key":"5109_CR24","first-page":"77","volume":"36","author":"A Gunnlaugsson","year":"2022","unstructured":"Gunnlaugsson A et al (2022) A prospective phase II study of prostate-specific antigen-guided salvage radiotherapy and (68)Ga-PSMA-PET for biochemical relapse after radical prostatectomy - The PROPER 1 trial. Clin Transl Radiat Oncol 36:77\u201382","journal-title":"Clin Transl Radiat Oncol"},{"issue":"3","key":"5109_CR25","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.ijrobp.2019.11.001","volume":"106","author":"W Liu","year":"2020","unstructured":"Liu W et al (2020) A prospective study of 18F-DCFPyL PSMA PET\/CT restaging in recurrent prostate cancer following primary external beam radiotherapy or brachytherapy. Int J Radiat Oncol Biol Phys 106(3):546\u2013555","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"5109_CR26","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.2967\/jnumed.119.226381","volume":"60","author":"E Rousseau","year":"2019","unstructured":"Rousseau E et al (2019) A prospective study on (18)F-DCFPyL PSMA PET\/CT imaging in biochemical recurrence of prostate cancer. J Nucl Med 60(11):1587\u20131593","journal-title":"J Nucl Med"},{"issue":"6","key":"5109_CR27","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler WP et al (2019) Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol 5(6):856\u2013863","journal-title":"JAMA Oncol"},{"issue":"1","key":"5109_CR28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s00259-017-3818-x","volume":"45","author":"E Mena","year":"2018","unstructured":"Mena E et al (2018) Clinical impact of PSMA-based (18)F-DCFBC PET\/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy. Eur J Nucl Med Mol Imaging 45(1):4\u201311","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"5109_CR29","doi-asserted-by":"publisher","first-page":"240","DOI":"10.2967\/jnumed.120.261886","volume":"63","author":"JJ Cerci","year":"2022","unstructured":"Cerci JJ et al (2022) Diagnostic Performance and Clinical Impact of (68)Ga-PSMA-11 PET\/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study). J Nucl Med 63(2):240\u2013247","journal-title":"J Nucl Med"},{"key":"5109_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11123311","author":"J Kunikowska","year":"2022","unstructured":"Kunikowska J et al (2022) Ga-68-PSMA-11 PET\/CT in patients with biochemical recurrence of prostate cancer after primary treatment with curative intent-Impact of delayed imaging. J Clin Med. https:\/\/doi.org\/10.3390\/jcm11123311","journal-title":"J Clin Med"},{"issue":"5","key":"5109_CR31","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1007\/s11307-022-01724-2","volume":"24","author":"K De Man","year":"2022","unstructured":"De Man K et al (2022) Impact of (18)F-PSMA-11 PET\/CT on Management of Biochemical Recurrence and High-Risk Prostate Cancer Staging\u202f: (18)F-PSMA-11 PET\/CT and Impact on Prostate Cancer Management. Mol Imaging Biol 24(5):750\u2013758","journal-title":"Mol Imaging Biol"},{"issue":"1","key":"5109_CR32","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.eururo.2024.01.012","volume":"86","author":"WR Armstrong","year":"2024","unstructured":"Armstrong WR et al (2024) Impact of prostate-specific membrane antigen positron emission tomography\/computed tomography on prostate cancer salvage radiotherapy management: results from a prospective multicenter randomized phase 3 trial (PSMA-SRT NCT03582774). Eur Urol 86(1):52\u201360","journal-title":"Eur Urol"},{"issue":"12","key":"5109_CR33","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.2967\/jnumed.120.242180","volume":"61","author":"WP Fendler","year":"2020","unstructured":"Fendler WP et al (2020) Impact of (68)Ga-PSMA-11 PET on the management of recurrent prostate cancer in a prospective single-arm clinical trial. J Nucl Med 61(12):1793\u20131799","journal-title":"J Nucl Med"},{"issue":"5","key":"5109_CR34","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.ijrobp.2020.07.014","volume":"108","author":"S Bergamin","year":"2020","unstructured":"Bergamin S et al (2020) Interim results of a prospective prostate-specific membrane antigen-directed focal stereotactic reirradiation trial for locally recurrent prostate cancer. Int J Radiat Oncol Biol Phys 108(5):1172\u20131178","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"5109_CR35","doi-asserted-by":"publisher","first-page":"546","DOI":"10.2967\/jnumed.119.231654","volume":"61","author":"H Song","year":"2020","unstructured":"Song H et al (2020) Prospective evaluation of (18)F-DCFPyL PET\/CT in biochemically recurrent prostate cancer in an academic center: a focus on disease localization and changes in management. J Nucl Med 61(4):546\u2013551","journal-title":"J Nucl Med"},{"issue":"11","key":"5109_CR36","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.3390\/cancers14112717","volume":"14","author":"S Ong","year":"2022","unstructured":"Ong S et al (2022) PSMA PET-CT imaging predicts treatment progression in men with biochemically recurrent prostate cancer-a prospective study of men with 3 year follow up. Cancers (Basel) 14(11):2717","journal-title":"Cancers (Basel)"},{"issue":"6","key":"5109_CR37","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.euo.2018.04.017","volume":"1","author":"A Kneebone","year":"2018","unstructured":"Kneebone A et al (2018) Stereotactic body radiotherapy for oligometastatic prostate cancer detected via Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol Oncol 1(6):531\u2013537","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"5109_CR38","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s10585-020-10043-1","volume":"37","author":"A Joshi","year":"2020","unstructured":"Joshi A et al (2020) The clinical efficacy of PSMA PET\/MRI in biochemically recurrent prostate cancer compared with standard of care imaging modalities and confirmatory histopathology: results of a single-centre, prospective clinical trial. Clin Exp Metastasis 37(4):551\u2013560","journal-title":"Clin Exp Metastasis"},{"issue":"1","key":"5109_CR39","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2967\/jnumed.117.197160","volume":"59","author":"PJ Roach","year":"2018","unstructured":"Roach PJ et al (2018) The impact of (68)Ga-PSMA PET\/CT on management intent in prostate cancer: results of an Australian prospective multicenter study. J Nucl Med 59(1):82\u201388","journal-title":"J Nucl Med"},{"issue":"12","key":"5109_CR40","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.2967\/jnumed.117.196683","volume":"58","author":"L Emmett","year":"2017","unstructured":"Emmett L et al (2017) Treatment outcomes from (68)Ga-PSMA PET\/CT-informed salvage radiation treatment in men with rising PSA after radical prostatectomy: prognostic value of a negative PSMA PET. J Nucl Med 58(12):1972\u20131976","journal-title":"J Nucl Med"},{"issue":"2","key":"5109_CR41","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00259-017-3858-2","volume":"45","author":"B Grubm\u00fcller","year":"2018","unstructured":"Grubm\u00fcller B et al (2018) (68)Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making. Eur J Nucl Med Mol Imaging 45(2):235\u2013242","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"5109_CR42","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/bju.13739","volume":"120","author":"S Albisinni","year":"2017","unstructured":"Albisinni S et al (2017) Clinical impact of (68)Ga-prostate-specific membrane antigen (PSMA) positron emission tomography\/computed tomography (PET\/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach. BJU Int 120(2):197\u2013203","journal-title":"BJU Int"},{"issue":"1","key":"5109_CR43","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13550-016-0233-4","volume":"6","author":"C Bluemel","year":"2016","unstructured":"Bluemel C et al (2016) Impact of (68)Ga-PSMA PET\/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy. EJNMMI Res 6(1):78","journal-title":"EJNMMI Res"},{"issue":"1","key":"5109_CR44","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2967\/jnumed.117.192625","volume":"59","author":"A Afaq","year":"2018","unstructured":"Afaq A et al (2018) Impact of (68)Ga-Prostate-Specific Membrane Antigen PET\/CT on prostate cancer management. J Nucl Med 59(1):89\u201392","journal-title":"J Nucl Med"},{"issue":"1","key":"5109_CR45","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13014-017-0877-x","volume":"12","author":"S Zschaeck","year":"2017","unstructured":"Zschaeck S et al (2017) Intermediate-term outcome after PSMA-PET guided high-dose radiotherapy of recurrent high-risk prostate cancer patients. Radiat Oncol 12(1):140","journal-title":"Radiat Oncol"},{"issue":"4","key":"5109_CR46","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00066-017-1231-9","volume":"194","author":"C Henkenberens","year":"2018","unstructured":"Henkenberens C et al (2018) Patterns of relapse as determined by (68)Ga-PSMA ligand PET\/CT after radical prostatectomy: importance for tailoring and individualizing treatment. Strahlenther Onkol 194(4):303\u2013310","journal-title":"Strahlenther Onkol"},{"key":"5109_CR47","volume":"5","author":"J Jiang","year":"2023","unstructured":"Jiang J et al (2023) ((18)F)-PSMA-1007PET\/CT in patients with biochemical recurrence after radical prostatectomy: diagnostic performance and impact on treatment management. Res Diagn Interv Imaging 5:100021","journal-title":"Res Diagn Interv Imaging"},{"issue":"2","key":"5109_CR48","doi-asserted-by":"publisher","first-page":"234","DOI":"10.2967\/jnumed.118.211086","volume":"60","author":"SA Koerber","year":"2019","unstructured":"Koerber SA et al (2019) (68)Ga-PSMA-11 PET\/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients. J Nucl Med 60(2):234\u2013240","journal-title":"J Nucl Med"},{"issue":"2","key":"5109_CR49","doi-asserted-by":"publisher","first-page":"230","DOI":"10.2967\/jnumed.117.201749","volume":"59","author":"J Calais","year":"2018","unstructured":"Calais J et al (2018) (68)Ga-PSMA-11 PET\/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng\/mL: Impact on Salvage Radiotherapy Planning. J Nucl Med 59(2):230\u2013237","journal-title":"J Nucl Med"},{"issue":"1","key":"5109_CR50","doi-asserted-by":"publisher","first-page":"157","DOI":"10.20892\/j.issn.2095-3941.2018.0288","volume":"16","author":"JSH Tan","year":"2019","unstructured":"Tan JSH et al (2019) (68)Gallium-labelled PSMA-PET\/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy. Cancer Biol Med 16(1):157\u2013166","journal-title":"Cancer Biol Med"},{"issue":"8","key":"5109_CR51","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00345-019-02701-1","volume":"37","author":"C Artigas","year":"2019","unstructured":"Artigas C et al (2019) (68)Ga-PSMA PET\/CT-based metastasis-directed radiotherapy for oligometastatic prostate cancer recurrence after radical prostatectomy. World J Urol 37(8):1535\u20131542","journal-title":"World J Urol"},{"issue":"1","key":"5109_CR52","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00259-018-4066-4","volume":"46","author":"A Farolfi","year":"2019","unstructured":"Farolfi A et al (2019) (68)Ga-PSMA-11 PET\/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5\u00a0ng\/ml. Efficacy and impact on treatment strategy. Eur J Nucl Med Mol Imaging 46(1):11\u201319","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"5109_CR53","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/pros.23751","volume":"79","author":"M Barbaud","year":"2019","unstructured":"Barbaud M et al (2019) 68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes. Prostate 79(5):454\u2013461","journal-title":"Prostate"},{"key":"5109_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.665304","volume":"11","author":"D Bottke","year":"2021","unstructured":"Bottke D et al (2021) Changes of radiation treatment concept based on (68)Ga-PSMA-11-PET\/CT in early PSA-recurrences after radical prostatectomy. Front Oncol 11:665304","journal-title":"Front Oncol"},{"issue":"1","key":"5109_CR55","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00259-020-04777-z","volume":"48","author":"AK Stefan","year":"2021","unstructured":"Stefan AK et al (2021) Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer. Eur J Nucl Med Mol Imaging 48(1):143\u2013151","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"5109_CR56","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.eururo.2022.05.031","volume":"83","author":"S Knipper","year":"2023","unstructured":"Knipper S et al (2023) Cohort study of oligorecurrent prostate cancer patients: oncological outcomes of patients treated with salvage lymph node dissection via Prostate-specific Membrane Antigen-radioguided surgery. Eur Urol 83(1):62\u201369","journal-title":"Eur Urol"},{"issue":"9","key":"5109_CR57","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s11547-018-0890-7","volume":"123","author":"B De Bari","year":"2018","unstructured":"De Bari B et al (2018) Could 68-Ga PSMA PET\/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series. Radiol Med 123(9):719\u2013725","journal-title":"Radiol Med"},{"issue":"12","key":"5109_CR58","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.2967\/jnumed.120.260091","volume":"62","author":"I Rauscher","year":"2021","unstructured":"Rauscher I et al (2021) Detection efficacy of (18)F-rhPSMA-7.3 PET\/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment. J Nucl Med 62(12):1719\u20131726","journal-title":"J Nucl Med"},{"issue":"1","key":"5109_CR59","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s12885-020-06883-5","volume":"20","author":"AK Oehus","year":"2020","unstructured":"Oehus AK et al (2020) Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy. BMC Cancer 20(1):362","journal-title":"BMC Cancer"},{"issue":"11","key":"5109_CR60","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1007\/s00066-020-01629-5","volume":"196","author":"C Henkenberens","year":"2020","unstructured":"Henkenberens C et al (2020) Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy. Strahlenther Onkol 196(11):1006\u20131017","journal-title":"Strahlenther Onkol"},{"issue":"9","key":"5109_CR61","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1097\/MNM.0000000000001047","volume":"40","author":"T Davidson","year":"2019","unstructured":"Davidson T et al (2019) Gallium-68 prostate-specific membrane antigen PET-CT and the clinical management of prostate cancer. Nucl Med Commun 40(9):913\u2013919","journal-title":"Nucl Med Commun"},{"issue":"3","key":"5109_CR62","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.rpor.2020.03.024","volume":"25","author":"F Cou\u00f1ago","year":"2020","unstructured":"Cou\u00f1ago F et al (2020) Impact of (68)Ga-PSMA PET\/CT in the treatment of prostate cancer: initial experience in Spain. Rep Pract Oncol Radiother 25(3):405\u2013411","journal-title":"Rep Pract Oncol Radiother"},{"issue":"4","key":"5109_CR63","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00259-018-4249-z","volume":"46","author":"U Bashir","year":"2019","unstructured":"Bashir U et al (2019) Impact of Ga-68-PSMA PET\/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatectomy. Eur J Nucl Med Mol Imaging 46(4):901\u2013907","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"5109_CR64","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1007\/s00259-020-04708-y","volume":"47","author":"NS Schmidt-Hegemann","year":"2020","unstructured":"Schmidt-Hegemann NS et al (2020) Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy-a multicenter retrospective study. Eur J Nucl Med Mol Imaging 47(8):1852\u20131863","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"5109_CR65","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/bju.13919","volume":"120","author":"A Siriwardana","year":"2017","unstructured":"Siriwardana A et al (2017) Initial multicentre experience of (68) gallium-PSMA PET\/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited. BJU Int 120(5):673\u2013681","journal-title":"BJU Int"},{"issue":"10","key":"5109_CR66","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1007\/s00259-020-04718-w","volume":"47","author":"J Miksch","year":"2020","unstructured":"Miksch J et al (2020) Interobserver variability, detection rate, and lesion patterns of (68)Ga-PSMA-11-PET\/CT in early-stage biochemical recurrence of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 47(10):2339\u20132347","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"5109_CR67","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1007\/s00259-021-05222-5","volume":"48","author":"D Meijer","year":"2021","unstructured":"Meijer D et al (2021) Management impact of (18)F-DCFPyL PET\/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study. Eur J Nucl Med Mol Imaging 48(9):2960\u20132969","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"5109_CR68","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.clgc.2020.08.002","volume":"19","author":"R Mazzola","year":"2021","unstructured":"Mazzola R et al (2021) Metastasis-directed therapy (SBRT) guided by PET-CT (18)F-CHOLINE versus PET-CT (68)Ga-PSMA in castration-sensitive oligorecurrent prostate cancer: a comparative analysis of effectiveness. Clin Genitourin Cancer 19(3):230\u2013236","journal-title":"Clin Genitourin Cancer"},{"key":"5109_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194982","author":"C Artigas","year":"2021","unstructured":"Artigas C et al (2021) Oligometastatic disease detection with (68)Ga-PSMA-11 PET\/CT in hormone-sensitive prostate cancer patients (HSPC) with biochemical recurrence after radical prostatectomy: Predictive factors and clinical impact. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13194982","journal-title":"Cancers (Basel)"},{"issue":"2","key":"5109_CR70","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2967\/jnumed.118.212563","volume":"60","author":"NS Schmidt-Hegemann","year":"2019","unstructured":"Schmidt-Hegemann NS et al (2019) Outcome after PSMA PET\/CT based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a bi-institutional retrospective analysis. J Nucl Med 60(2):227\u2013233","journal-title":"J Nucl Med"},{"issue":"4","key":"5109_CR71","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s00259-021-05557-z","volume":"49","author":"P Rogowski","year":"2022","unstructured":"Rogowski P et al (2022) Outcome after PSMA-PET\/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy. Eur J Nucl Med Mol Imaging 49(4):1417\u20131428","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"5109_CR72","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1007\/s00259-017-3746-9","volume":"44","author":"K Schiller","year":"2017","unstructured":"Schiller K et al (2017) Patterns of failure after radical prostatectomy in prostate cancer - implications for radiation therapy planning after (68)Ga-PSMA-PET imaging. Eur J Nucl Med Mol Imaging 44(10):1656\u20131662","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"5109_CR73","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ijrobp.2018.08.066","volume":"103","author":"A Soldatov","year":"2019","unstructured":"Soldatov A et al (2019) Patterns of Progression After (68)Ga-PSMA-Ligand PET\/CT-Guided Radiation Therapy for Recurrent Prostate Cancer. Int J Radiat Oncol Biol Phys 103(1):95\u2013104","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"5109_CR74","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1007\/s00259-020-04760-8","volume":"47","author":"MME Vogel","year":"2020","unstructured":"Vogel MME et al (2020) Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [(68)Ga]PSMA-PET-guided metastasis-directed therapy. Eur J Nucl Med Mol Imaging 47(10):2328\u20132338","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"5109_CR75","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.euf.2019.08.012","volume":"7","author":"SGC Kroeze","year":"2021","unstructured":"Kroeze SGC et al (2021) Prostate-specific membrane antigen positron emission tomography-detected oligorecurrent prostate cancer treated with metastases-directed radiotherapy: role of addition and duration of androgen deprivation. Eur Urol Focus 7(2):309\u2013316","journal-title":"Eur Urol Focus"},{"issue":"2","key":"5109_CR76","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.euo.2022.01.001","volume":"5","author":"D Meijer","year":"2022","unstructured":"Meijer D et al (2022) Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography is associated with improved oncological outcome in men treated with salvage radiation therapy for biochemically recurrent prostate cancer. Eur Urol Oncol 5(2):146\u2013152","journal-title":"Eur Urol Oncol"},{"issue":"8","key":"5109_CR77","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1007\/s00259-023-06185-5","volume":"50","author":"N Solomonidou","year":"2023","unstructured":"Solomonidou N et al (2023) PSMA-PET\/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA\u2009<\u20090.2\u00a0ng\/ml. Eur J Nucl Med Mol Imaging 50(8):2529\u20132536","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5109_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071594","author":"A Fourquet","year":"2021","unstructured":"Fourquet A et al (2021) Restaging the biochemical recurrence of prostate cancer with [(68)Ga]Ga-PSMA-11 PET\/CT: diagnostic performance and impact on patient disease management. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13071594","journal-title":"Cancers (Basel)"},{"issue":"7","key":"5109_CR79","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1007\/s00066-018-1291-5","volume":"194","author":"T Frenzel","year":"2018","unstructured":"Frenzel T et al (2018) The impact of [(68)Ga]PSMA I&T PET\/CT on radiotherapy planning in patients with prostate cancer. Strahlenther Onkol 194(7):646\u2013654","journal-title":"Strahlenther Onkol"},{"issue":"3","key":"5109_CR80","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00259-019-04643-7","volume":"47","author":"M Kulkarni","year":"2020","unstructured":"Kulkarni M et al (2020) The management impact of (68)gallium-tris(hydroxypyridinone) prostate-specific membrane antigen ((68)Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer. Eur J Nucl Med Mol Imaging 47(3):674\u2013686","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"5109_CR81","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s00259-023-06438-3","volume":"51","author":"S Adebahr","year":"2024","unstructured":"Adebahr S et al (2024) The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy. Eur J Nucl Med Mol Imaging 51(2):558\u2013567","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"5109_CR82","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/pcan.2016.54","volume":"20","author":"D Porres","year":"2017","unstructured":"Porres D et al (2017) The role of salvage extended lymph node dissection in patients with rising PSA and PET\/CT scan detected nodal recurrence of prostate cancer. Prostate Cancer Prostatic Dis 20(1):85\u201392","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"5109_CR83","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","volume":"70","author":"M Perera","year":"2016","unstructured":"Perera M et al (2016) Sensitivity, specificity, and predictors of positive (68)Ga-Prostate-specific Membrane Antigen positron emission tomography in advanced prostate cancer: A systematic review and meta-analysis. Eur Urol 70(6):926\u2013937","journal-title":"Eur Urol"},{"issue":"4","key":"5109_CR84","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"M Perera","year":"2020","unstructured":"Perera M et al (2020) Gallium-68 Prostate-specific Membrane Antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of Prostate-specific Membrane Antigen-avid lesions: A systematic review and meta-analysis. Eur Urol 77(4):403\u2013417","journal-title":"Eur Urol"},{"issue":"2","key":"5109_CR85","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41391-022-00544-3","volume":"26","author":"A Pozdnyakov","year":"2023","unstructured":"Pozdnyakov A et al (2023) The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 26(2):240\u2013248","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"5109_CR86","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.eururo.2018.03.030","volume":"74","author":"S Han","year":"2018","unstructured":"Han S et al (2018) Impact of (68)Ga-PSMA PET on the management of patients with prostate cancer: A systematic review and meta-analysis. Eur Urol 74(2):179\u2013190","journal-title":"Eur Urol"},{"issue":"3","key":"5109_CR87","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/endrev\/bnab002","volume":"42","author":"K Desai","year":"2021","unstructured":"Desai K, McManus JM, Sharifi N (2021) Hormonal therapy for prostate cancer. Endocr Rev 42(3):354\u2013373","journal-title":"Endocr Rev"},{"issue":"5","key":"5109_CR88","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.eururo.2015.11.023","volume":"69","author":"RC van den Bergh","year":"2016","unstructured":"van den Bergh RC et al (2016) Role of hormonal treatment in prostate cancer patients with nonmetastatic disease recurrence after local curative treatment: A systematic review. Eur Urol 69(5):802\u2013820","journal-title":"Eur Urol"},{"issue":"2","key":"5109_CR89","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/bju.13203","volume":"118","author":"M Schmid","year":"2016","unstructured":"Schmid M et al (2016) Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events. BJU Int 118(2):221\u2013229","journal-title":"BJU Int"},{"issue":"3","key":"5109_CR90","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s00259-017-3895-x","volume":"45","author":"FE von Eyben","year":"2018","unstructured":"von Eyben FE et al (2018) Third-line treatment and (177)Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging 45(3):496\u2013508","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"5109_CR91","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/jnumed.116.183194","volume":"58","author":"K Rahbar","year":"2017","unstructured":"Rahbar K et al (2017) German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. J Nucl Med 58(1):85\u201390","journal-title":"J Nucl Med"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05109-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05109-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05109-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:03:04Z","timestamp":1787659384000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05109-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":91,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["5109"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05109-0","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}